vs
CareTrust REIT, Inc.（CTRE）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
CareTrust REIT, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.8倍（$134.9M vs $75.5M），CareTrust REIT, Inc.同比增速更快（55.1% vs 27.7%），过去两年CareTrust REIT, Inc.的营收复合增速更高（46.2% vs 31.3%）
本公司是一家英国房地产投资企业，专注于医疗类不动产投资，持有规模庞大的养老护理院资产组合。公司采用房地产投资信托（REIT）架构，在伦敦证券交易所上市，是富时250指数成分股。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CTRE vs PBYI — 直观对比
营收规模更大
CTRE
是对方的1.8倍
$75.5M
营收增速更快
CTRE
高出27.4%
27.7%
两年增速更快
CTRE
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $134.9M | $75.5M |
| 净利润 | $111.3M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | — | 22.7% |
| 净利率 | 82.5% | — |
| 营收同比 | 55.1% | 27.7% |
| 净利润同比 | 113.5% | — |
| 每股收益（稀释后） | $0.52 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTREPBYI
| Q4 25 | $134.9M | $75.5M | ||
| Q3 25 | $132.4M | $54.5M | ||
| Q2 25 | $112.5M | $52.4M | ||
| Q1 25 | $96.6M | $46.0M | ||
| Q4 24 | $86.9M | $59.1M | ||
| Q3 24 | $77.4M | $80.5M | ||
| Q2 24 | $68.9M | $47.1M | ||
| Q1 24 | $63.1M | $43.8M |
净利润CTREPBYI
| Q4 25 | $111.3M | — | ||
| Q3 25 | $74.9M | $8.8M | ||
| Q2 25 | $68.5M | $5.9M | ||
| Q1 25 | $65.8M | $3.0M | ||
| Q4 24 | $52.1M | — | ||
| Q3 24 | $33.4M | $20.3M | ||
| Q2 24 | $10.8M | $-4.5M | ||
| Q1 24 | $28.7M | $-4.8M |
毛利率CTREPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率CTREPBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | 58.1% | 17.6% | ||
| Q2 25 | 61.3% | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | 43.0% | 27.4% | ||
| Q2 24 | 15.1% | -4.6% | ||
| Q1 24 | — | -5.3% |
净利率CTREPBYI
| Q4 25 | 82.5% | — | ||
| Q3 25 | 56.6% | 16.2% | ||
| Q2 25 | 60.9% | 11.2% | ||
| Q1 25 | 68.1% | 6.5% | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 43.2% | 25.2% | ||
| Q2 24 | 15.6% | -9.6% | ||
| Q1 24 | 45.6% | -11.0% |
每股收益（稀释后）CTREPBYI
| Q4 25 | $0.52 | $0.26 | ||
| Q3 25 | $0.35 | $0.17 | ||
| Q2 25 | $0.35 | $0.12 | ||
| Q1 25 | $0.35 | $0.06 | ||
| Q4 24 | $0.30 | $0.40 | ||
| Q3 24 | $0.21 | $0.41 | ||
| Q2 24 | $0.07 | $-0.09 | ||
| Q1 24 | $0.22 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.0M | $97.5M |
| 总债务越低越好 | $894.2M | $22.7M |
| 股东权益账面价值 | $4.0B | $130.3M |
| 总资产 | $5.1B | $216.3M |
| 负债/权益比越低杠杆越低 | 0.22× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CTREPBYI
| Q4 25 | $198.0M | $97.5M | ||
| Q3 25 | $712.5M | $94.4M | ||
| Q2 25 | $306.1M | $96.0M | ||
| Q1 25 | $26.5M | $93.2M | ||
| Q4 24 | $213.8M | $101.0M | ||
| Q3 24 | $377.1M | $96.7M | ||
| Q2 24 | $495.1M | $96.8M | ||
| Q1 24 | $451.2M | $107.2M |
总债务CTREPBYI
| Q4 25 | $894.2M | $22.7M | ||
| Q3 25 | $893.8M | $34.0M | ||
| Q2 25 | $1.2B | $45.3M | ||
| Q1 25 | $822.1M | $56.7M | ||
| Q4 24 | $396.9M | $68.0M | ||
| Q3 24 | $396.7M | $79.3M | ||
| Q2 24 | $671.1M | $90.7M | ||
| Q1 24 | $595.9M | $102.0M |
股东权益CTREPBYI
| Q4 25 | $4.0B | $130.3M | ||
| Q3 25 | $4.0B | $115.3M | ||
| Q2 25 | $3.3B | $104.7M | ||
| Q1 25 | $2.9B | $97.1M | ||
| Q4 24 | $2.9B | $92.1M | ||
| Q3 24 | $2.4B | $71.1M | ||
| Q2 24 | $1.9B | $48.5M | ||
| Q1 24 | $1.7B | $51.0M |
总资产CTREPBYI
| Q4 25 | $5.1B | $216.3M | ||
| Q3 25 | $5.1B | $202.9M | ||
| Q2 25 | $4.7B | $194.9M | ||
| Q1 25 | $3.9B | $196.2M | ||
| Q4 24 | $3.4B | $213.3M | ||
| Q3 24 | $2.9B | $220.7M | ||
| Q2 24 | $2.7B | $205.0M | ||
| Q1 24 | $2.3B | $214.1M |
负债/权益比CTREPBYI
| Q4 25 | 0.22× | 0.17× | ||
| Q3 25 | 0.22× | 0.30× | ||
| Q2 25 | 0.35× | 0.43× | ||
| Q1 25 | 0.28× | 0.58× | ||
| Q4 24 | 0.14× | 0.74× | ||
| Q3 24 | 0.16× | 1.12× | ||
| Q2 24 | 0.35× | 1.87× | ||
| Q1 24 | 0.36× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $394.0M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 3.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流CTREPBYI
| Q4 25 | $394.0M | $14.4M | ||
| Q3 25 | $100.9M | $9.7M | ||
| Q2 25 | $100.8M | $14.1M | ||
| Q1 25 | $71.4M | $3.6M | ||
| Q4 24 | $244.3M | $15.6M | ||
| Q3 24 | $67.2M | $11.0M | ||
| Q2 24 | $53.0M | $1.0M | ||
| Q1 24 | $48.8M | $11.2M |
自由现金流CTREPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率CTREPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度CTREPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率CTREPBYI
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | 1.10× | ||
| Q2 25 | 1.47× | 2.41× | ||
| Q1 25 | 1.08× | 1.21× | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | 0.54× | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
